Redirecting to https://apnews.com/press-release/pr-newswire/the-snda-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-accepted-for-review-by-nmpa-95c344f895d3d0ecafff12b6b7bf0962